EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression

Iva Brcic iD, Andrea Maria Kluba, Theresa Marie Godschachner, Christoph Suppan, Peter Regitnig iD, Nadia Dandachi iD, Sigurd Friedwald Lax, Marija Balić iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24010818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Iva Brcic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Research Institute of Pathology, Comprehensive Cancer Centre, Medical University of Graz, 8010 Graz, Austria. Hauptthemen laut MEDLINE: Breast Neoplasms, Male, Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Male breast cancer (MBC) is rare and usually presents as a locally advanced disease. Stromal tumor-infiltrating lymphocytes (sTILs) are associated with a better response to neoadjuvant chemotherapy and improved prognosis in all molecular subtypes of female breast cancer, but their role in MBC is less clear. We studied sTILs and the expression of programmed cell death ligand 1 (PD-L1) and pan-TRK in MBC. We retrospectively studied 113 cases of MBC surgically treated between 1988 and 2015. The tumors were evaluated for histological type and grade, stage, intrinsic subtype and sTILs. We performed immunohistochemistry for PD-L1 (clone SP142) and pan-TRK (clone EPR17341) on tissue microarrays. Pan-TRK positive cases were further analyzed by next-generation sequencing. The median age was 69 years (range 60–77). Invasive carcinoma of no special type was found in 94.7% of cases, of which 53.1% were grade 2. Estrogen receptor was positive in 92% of the tumors, progesterone receptor in 85.8%, androgen receptor in 70.8%; 4.4% were human epidermal growth factor receptor 2 (HER2)-positive, and 55.8% HER2-low. 40.7% of tumors were luminal A and 51.3% luminal B, 4.4% HER2-enriched and 3.5% triple negative carcinoma. sTILs density was 50% in 3.6% of the tumors. PD-L1 immune cell score >1% was found in 7.1% of the tumors (all of luminal subtype). A weak focal cytoplasmic pan-TRK staining was present in 8.8% but without NTRK fusion. Neither sTILs nor PD-L1 had statistically significant outcomes. Our findings suggest that a subset of MBC patients harbors an immunological environment characterized by increased sTILs with PD-L1 expression. These patients may potentially benefit from immune checkpoint inhibitor therapy. Frequent HER2-low may offer novel anti-HER2 treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast Neoplasms, MaleBreast NeoplasmsTriple Negative Breast NeoplasmsFemaleHumansMaleMiddle AgedAgedLymphocytes, Tumor-InfiltratingB7-H1 AntigenTumor MicroenvironmentRetrospective StudiesBiomarkers, Tumor

Stichwörter der Autor:innen

HER2-lowPD-L1TILsintrinsic subtypesmale breast cancerpan-TRK

Substanzen

B7-H1 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Diagnostic and Research Institute of Pathology, Comprehensive Cancer Centre, Medical University of Graz, 8010 Graz, Austria.
  • Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
  • Research Unit for Epigenetic and Genetic Cancer Biomarkers, Medical University of Graz, 8036 Graz, Austria.
  • Department of Pathology, Hospital Graz II, Academic Teaching Hospital of the Medical University Graz, 8020 Graz, Austria.
  • School of Medicine, Johannes Kepler University Linz, 4020 Linz, Austria.
  • Unit for Translational Breast Cancer Research, Medical University of Graz, 8036 Graz, Austria.

ORCID-Profile: Iva Brcic, Peter Regitnig, Nadia Dandachi, Marija Balić

Förderung

  • Pfizer

Zitieren

APA

Brcic, I., Kluba, A. M., Godschachner, T. M., Suppan, C., Regitnig, P., Dandachi, N., Lax, S. F., & Balić, M. (2023). Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24010818

Vancouver

Brcic I, Kluba AM, Godschachner TM, Suppan C, Regitnig P, Dandachi N, et al. Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24010818

BibTeX
@article{Brcic2023,
  author = {Brcic, Iva and Kluba, Andrea Maria and Godschachner, Theresa Marie and Suppan, Christoph and Regitnig, Peter and Dandachi, Nadia and Lax, Sigurd Friedwald and Balić, Marija},
  title = {Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24010818}
}
Kostenlos starten →